Natera (NASDAQ:NTRA) Insider Sells $188,575.52 in Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 784 shares of the company’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $240.53, for a total value of $188,575.52. Following the completion of the transaction, the insider directly owned 176,468 shares in the company, valued at $42,445,848.04. This trade represents a 0.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

John Fesko also recently made the following trade(s):

• On Wednesday, January 28th, John Fesko sold 928 shares of Natera stock. The stock was sold at an average price of $237.66, for a total value of $220,548.48.
• On Wednesday, January 21st, John Fesko sold 339 shares of Natera stock. The stock was sold at an average price of $235.00, for a total transaction of $79,665.00.
• On Tuesday, January 20th, John Fesko sold 17,806 shares of Natera stock. The stock was sold at an average price of $234.74, for a total transaction of $4,179,780.44.

Natera Price Performance

Natera stock opened at $231.14 on Friday. The stock has a market cap of $31.97 billion, a price-to-earnings ratio of -100.93 and a beta of 1.62. The firm has a 50-day moving average of $235.91 and a two-hundred day moving average of $194.11. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $256.36.

Natera (NASDAQ:NTRA) last issued its earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The company had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business’s revenue was up 34.7% compared to the same quarter last year. During the same period last year, the business posted ($0.26) earnings per share. Research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of NTRA. Sigma Planning Corp bought a new position in shares of Natera during the 4th quarter worth approximately $700,000. Citizens Financial Group Inc. RI purchased a new position in Natera in the fourth quarter worth $271,000. Precision Wealth Strategies LLC increased its position in shares of Natera by 29.5% during the fourth quarter. Precision Wealth Strategies LLC now owns 5,794 shares of the medical research company’s stock worth $1,327,000 after purchasing an additional 1,319 shares in the last quarter. Trifecta Capital Advisors LLC purchased a new stake in shares of Natera during the 4th quarter valued at $115,000. Finally, Moody Aldrich Partners LLC acquired a new stake in shares of Natera in the 4th quarter worth $269,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced completion of enrollment in the randomized ACES‑EMB heart‑transplant trial — a clinical milestone for the transplant franchise (Prospera) that de‑risks the program’s pathway to clinical readouts and potential uptake. Article Title
• Positive Sentiment: Wall Street coverage remains largely favorable: multiple firms maintain buy/outperform views and several have raised targets (MarketBeat summary shows consensus around a “Moderate Buy” and an average target near $249). This supports upside expectations if results and growth continue.
• Neutral Sentiment: Natera reported preliminary Q4 revenue (details in the alert). Preliminary figures may influence sentiment when the final quarter report and guidance are released; investors should watch the formal Q4 release for confirmation versus consensus. Preliminary Q4 Revenue
• Neutral Sentiment: Institutional ownership remains extremely high (~99.9%), which tends to stabilize the shareholder base but can also concentrate selling/Buying flows when large holders move. (Source: MarketBeat summary.) Institutional Data
• Negative Sentiment: Multiple insider sales by senior executives: CFO Michael Burkes Brophy sold several tranches (totaling 5,064 shares across Jan. 20–29) and CEO Steven Chapman sold several thousand shares (roughly 5,970 shares across Jan. 27–28). These trades total millions of dollars and may create short‑term selling pressure despite insiders retaining large residual stakes. CFO Form 4 CEO Form 4
• Negative Sentiment: Other insiders (John Fesko, Solomon Moshkevich) also sold smaller tranches. While each reduction is under ~1% of those insiders’ holdings, the cluster of sales amplifies negative signaling to the market. Fesko Form 4 Moshkevich Form 4

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on NTRA. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. UBS Group increased their target price on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. JPMorgan Chase & Co. boosted their price target on shares of Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Evercore ISI upped their price target on shares of Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Finally, BNP Paribas Exane upgraded shares of Natera to a “hold” rating and set a $172.00 price objective on the stock in a research note on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $249.20.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.